Patient-reported outcome measures 2 years after treatment of small ventral hernias using a monofilament polypropylene patch covered with an absorbable hydrogel barrier on its visceral side

Abstract

BACKGROUND: In spite of their wide use, clinical studies on intraperitoneal ventral patches are rare, especially for VentralexTM ST (VST), recently released. MATERIALS AND METHODS: Two-year results of 108 patients operated on from a ventral hernia with VST were assessed using a patient-reported outcome measures concept. RESULTS: One hundred and eight patients (59.9 ± 14.65 years; body mass index 29.72 ± 8.14; wound healing risk factor in 49 patients) were prospectively registered. Surgery was clean in 105 (97%) or clean contaminated in 3 (3%). The defect was CONCLUSION: Despite potential underestimation of recurrences and rare long-term complications, this study, the first one on this new patch, suggests that VST could be safe and effective in the treatment of small primary or incisional ventral hernias. However, further studies are needed to confirm these preliminary results.